Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial

Scott M Grundy, Gloria L Vega, Mark E. McGovern, Brian R. Tulloch, David M. Kendall, David Fitz-Patrick, Om P. Ganda, Robert S. Rosenson, John B. Buse, David D. Robertson, John P. Sheehan

Research output: Contribution to journalArticlepeer-review

506 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial'. Together they form a unique fingerprint.

Medicine & Life Sciences